JP2023519199A - トレプロスチニルプロドラッグの医薬製剤及びその使用方法 - Google Patents

トレプロスチニルプロドラッグの医薬製剤及びその使用方法 Download PDF

Info

Publication number
JP2023519199A
JP2023519199A JP2022556050A JP2022556050A JP2023519199A JP 2023519199 A JP2023519199 A JP 2023519199A JP 2022556050 A JP2022556050 A JP 2022556050A JP 2022556050 A JP2022556050 A JP 2022556050A JP 2023519199 A JP2023519199 A JP 2023519199A
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
mdi
formula
ngi
measured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519199A5 (https=
Inventor
マリニン，ウラジミール
プラウント，アダム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of JP2023519199A publication Critical patent/JP2023519199A/ja
Publication of JP2023519199A5 publication Critical patent/JP2023519199A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022556050A 2020-03-25 2021-03-25 トレプロスチニルプロドラッグの医薬製剤及びその使用方法 Pending JP2023519199A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994596P 2020-03-25 2020-03-25
US62/994,596 2020-03-25
PCT/US2021/024077 WO2021195328A1 (en) 2020-03-25 2021-03-25 Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023519199A true JP2023519199A (ja) 2023-05-10
JP2023519199A5 JP2023519199A5 (https=) 2024-03-14

Family

ID=77892300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556050A Pending JP2023519199A (ja) 2020-03-25 2021-03-25 トレプロスチニルプロドラッグの医薬製剤及びその使用方法

Country Status (4)

Country Link
US (1) US20240238309A1 (https=)
EP (1) EP4126856A4 (https=)
JP (1) JP2023519199A (https=)
WO (1) WO2021195328A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024069403A (ja) * 2019-04-29 2024-05-21 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860975T3 (es) 2013-10-25 2021-10-05 Insmed Inc Compuestos de prostaciclina
WO2022094100A1 (en) * 2020-10-28 2022-05-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
CN121001747A (zh) * 2023-04-03 2025-11-21 菲沃瑞特制药 治疗转移性癌症和其他癌症的药物组合物和方法
WO2025147662A1 (en) * 2024-01-04 2025-07-10 Insmed Incorporated Methods of treatment using dry powder compositions of treprostinil prodrugs

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521424A (ja) * 1998-07-24 2002-07-16 ヤゴ・リサーチ・アクチェンゲゼルシャフト 医薬用エーロゾル製剤
JP2002522374A (ja) * 1998-08-04 2002-07-23 ヤゴ・リサーチ・アクチェンゲゼルシャフト 医薬用エーロゾル製剤
JP2003518484A (ja) * 1999-12-24 2003-06-10 グラクソ グループ リミテッド サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤
JP2011510963A (ja) * 2008-02-01 2011-04-07 ベクトゥラ・リミテッド 懸濁製剤
JP2014527056A (ja) * 2011-03-17 2014-10-09 益得生物科技股▲ふん▼有限公司 呼吸器疾患を治療するための定量噴霧式吸入剤を調製する方法
WO2015138423A1 (en) * 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
JP2016540734A (ja) * 2013-10-25 2016-12-28 インスメッド， インコーポレイテッド プロスタサイクリン化合物、組成物およびその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114652704A (zh) * 2022-04-29 2022-06-24 兆科药业（广州）有限公司 一种曲前列尼尔软雾吸入剂

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521424A (ja) * 1998-07-24 2002-07-16 ヤゴ・リサーチ・アクチェンゲゼルシャフト 医薬用エーロゾル製剤
JP2002522374A (ja) * 1998-08-04 2002-07-23 ヤゴ・リサーチ・アクチェンゲゼルシャフト 医薬用エーロゾル製剤
JP2003518484A (ja) * 1999-12-24 2003-06-10 グラクソ グループ リミテッド サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤
JP2011510963A (ja) * 2008-02-01 2011-04-07 ベクトゥラ・リミテッド 懸濁製剤
JP2014527056A (ja) * 2011-03-17 2014-10-09 益得生物科技股▲ふん▼有限公司 呼吸器疾患を治療するための定量噴霧式吸入剤を調製する方法
JP2016540734A (ja) * 2013-10-25 2016-12-28 インスメッド， インコーポレイテッド プロスタサイクリン化合物、組成物およびその使用方法
WO2015138423A1 (en) * 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PULMONARY PHARMACOLOGY & THERAPEUTICS, vol. 49, JPN6025005649, 2018, pages 104 - 111, ISSN: 0005527530 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024069403A (ja) * 2019-04-29 2024-05-21 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP7732017B2 (ja) 2019-04-29 2025-09-01 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法

Also Published As

Publication number Publication date
EP4126856A1 (en) 2023-02-08
WO2021195328A1 (en) 2021-09-30
EP4126856A4 (en) 2024-05-01
US20240238309A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
JP2023519199A (ja) トレプロスチニルプロドラッグの医薬製剤及びその使用方法
JP7430766B2 (ja) プロスタサイクリン化合物、組成物およびその使用方法
TWI539979B (zh) 用於經由肺部遞送長效蕈毒鹼拮抗劑及長效β腎上腺素受體激動劑之組成物，及相關方法及系統
US12201725B2 (en) Dry powder compositions of treprostinil prodrugs and methods of use thereof
AU2014339866A1 (en) Prostacyclin compounds, compositions and methods of use thereof
TWI468187B (zh) 可吸入式藥劑
US20250248960A1 (en) Methods for Providing Rapid Relief of Motor Fluctuations in a Parkinson's Disease Patient
EP4188332B1 (en) Device for treating anaphylaxis
AU2020250280B2 (en) Reducing Inter-Patient Variability of Levodopa Plasma Concentrations
WO2025072756A1 (en) Device, methods, and uses for treating acute allergic reactions
HK40071377A (en) Levodopa formulations for rapid relief of parkinson’s disease
JP2026509493A (ja) 噴霧乾燥トレプロスチニル製剤
HK40051638A (en) Prostacyclin compounds
HK40087057A (en) Device for treating anaphylaxis
HK1225229A1 (en) Prostacyclin compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250808